{"id":"methylergometrine","rwe":[],"_fda":{"id":"0c5bd53a-48a3-4892-aeaf-ea0abc73e612","set_id":"3f04ca06-fe52-46d6-96cd-2e77ef6fa36f","openfda":{"unii":["IR84JPZ1RK"],"route":["ORAL"],"rxcui":["996824","996826"],"spl_id":["0c5bd53a-48a3-4892-aeaf-ea0abc73e612"],"brand_name":["Methergine"],"spl_set_id":["3f04ca06-fe52-46d6-96cd-2e77ef6fa36f"],"package_ndc":["27437-050-57","27437-050-56","27437-050-01","27437-050-19"],"product_ndc":["27437-050"],"generic_name":["METHYLERGONOVINE MALEATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["METHYLERGONOVINE MALEATE"],"manufacturer_name":["Lupin Pharmaceuticals,Inc."],"application_number":["ANDA091577"],"is_original_packager":[true]},"version":"3","warnings":["WARNINGS General This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V administration is considered essential as a lifesaving measure, Methergine (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided. Caution should be exercised in presence of impaired hepatic or renal function. Breast-feeding Mothers should not breast-feed during treatment with Methergine. Milk secreted during this period should be discarded. Methergine may produce adverse effects in the breast-feeding infant. Methergine may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of Methergine before initiating or resuming breast feeding. Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. Medication errors Inadvertent administration of Methergine to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as respiratory depression, convulsions, cyanosis and oliguria have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required. Methergine has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, Methergine injection should be stored separately from medications intended for neonatal administration."],"pregnancy":["Pregnancy Category C: Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE )."],"overdosage":["OVERDOSAGE Symptoms of acute overdose may include: nausea, vomiting, oliquria, abdominal pain, numbness, tingling of the extremities, rise in blood pressure, in severe cases followed by hypotension, respiratory depression, hypothermia, convulsions, and coma. Because reports of overdosage with Methergine (methylergonovine maleate) are infrequent, the lethal dose in humans has not been established. The oral LD 50 (in mg/kg) for the mouse is 187, the rat 93, and the rabbit 4.5 2 . Several cases of accidental Methergine injection in newborn infants have been reported, and in such cases 0.2 mg represents an overdose of great magnitude. However, recovery occurred in all but one case following a period of respiratory depression, hypothermia, hypertonicity with jerking movements, and convulsions. Also, several children 1-3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported paresthesias and clamminess as her only symptoms. Treatment of acute overdosage is symptomatic and includes the usual procedures of: removal of offending drug by inducing emesis, gastric lavage, catharsis, and supportive diuresis. maintenance of adequate pulmonary ventilation, especially if convulsions or coma develop. correction of hypotension with pressor drugs as needed. control of convulsions with standard anticonvulsant agents. control of peripheral vasospasm with warmth to the extremities if needed."],"description":["DESCRIPTION Methergine ® (methylergonovine maleate) is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage. Methergine is available in tablets for oral ingestion containing 0.2 mg methylergonovine maleate. Tablets Active ingredient: Methylergonovine maleate, USP, 0.2 mg. Inactive ingredients: acacia, corn starch, gelatin, lactose monohydrate, methylparaben, microcrystalline cellulose, povidone, propylparaben, stearic acid, and tartaric acid. Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9, 10-didehydro- N -[1-(hydroxymethyl) propyl]-6-methyl-, [8β( S )]-, (Z)-2-butenedioate (1:1) (salt). Its structural formula is: structure"],"precautions":["PRECAUTIONS General Caution should be exercised in the presence of sepsis, obliterative vascular disease. Also use with caution during the second stage of labor. The necessity for manual removal of a retained placenta should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation. Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine. Beta-blockers Caution should be exercised when Methergine is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothan and methoxyfluran may reduce the oxytocic potency of Methergine. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs. No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies have been performed in animals to evaluate carcinogenic potential. The effect of the drug on mutagenesis or fertility has not been determined. Pregnancy Category C: Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE ). Labor and Delivery The uterotonic effect of Methergine is utilized after delivery to assist involution and decrease hemorrhage, shortening the third stage of labor. Nursing Mothers Mothers should not breast-feed during treatment with Methergine and at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED White, round, biconvex compressed tablets debossed with \"n\" on one side and \"01\" on the other side. Available in bottles of 7, 12, 28 and 100 tablets. Bottles of 7………………………………NDC 27437-050-19 Bottles of 12…………………………….NDC 27437-050-57 Bottles of 28…………………………….NDC 27437-050-56 Bottles of 100………………………...…NDC 27437-050-01 STORE AND DISPENSE Tablets: Store below 25°C (77°F); in tight, light-resistant container. Methergine is a registered trademark of Novartis AG Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873 Manufactured for: Lupin Pharma Baltimore, MD 21202 PI1400003901 Iss. 01/2016"],"geriatric_use":["Geriatric Use Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20240320","nursing_mothers":["Nursing Mothers Mothers should not breast-feed during treatment with Methergine and at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded."],"adverse_reactions":["ADVERSE REACTIONS The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Abdominal pain (caused by uterine contractions), nausea and vomiting have occurred occasionally. Rarely observed reactions have included: acute myocardial infarction, transient chest pains, vasoconstriction, vasospasm, coronary arterial spasm, bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste. 1 There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. Postmarketing Experience The following adverse drug reactions have been derived from post-marketing experience with Methergine via spontaneous case reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Nervous system disorders Cerebrovascular accident, paraesthesia Cardiac disorders Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block"],"contraindications":["CONTRAINDICATIONS Hypertension; toxemia; pregnancy; and hypersensitivity."],"drug_interactions":["Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of Methergine. Beta-blockers Caution should be exercised when Methergine is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothan and methoxyfluran may reduce the oxytocic potency of Methergine. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs. No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known. Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins."],"labor_and_delivery":["Labor and Delivery The uterotonic effect of Methergine is utilized after delivery to assist involution and decrease hemorrhage, shortening the third stage of labor."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes. Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver. Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of Methergine solution was about 25% greater than the tablet. The volume of distribution (Vd ss /F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (T max about 3 hours) of Methergine tablet might be observed in postpartum women during continuous treatment with this oxytocic agent."],"indications_and_usage":["INDICATIONS AND USAGE Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Intramuscularly 1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours. Intravenously 1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See WARNINGS .) Orally One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Methergine (methylergonovine maleate) has not been associated with drug abuse or dependence of either a physical or psychological nature."],"spl_product_data_elements":["Methergine Methylergonovine maleate METHYLERGONOVINE MALEATE METHYLERGONOVINE ACACIA STARCH, CORN GELATIN LACTOSE MONOHYDRATE METHYLPARABEN CELLULOSE, MICROCRYSTALLINE POVIDONE K30 PROPYLPARABEN STEARIC ACID TARTARIC ACID biconvex n;01"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Methergine (methylergonovinemaleate) tablets, USP Container Labels 7 Count 12 Count 28 Count 100 Count 7 ct 12 ct 28 ct 100 ct"]},"tags":[{"label":"Ergot Derivative","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"HTR6","category":"gene"},{"label":"G02AB01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Postabortal Hemorrhage","category":"indication"},{"label":"Postpartum hemorrhage","category":"indication"},{"label":"Edison Theraps Llc","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Oxytocics","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":365.837,"date":"","count":74,"signal":"Wrong product administered","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=366)"},{"llr":72.704,"date":"","count":24,"signal":"Cyanosis","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=73)"},{"llr":61.719,"date":"","count":23,"signal":"Accidental exposure to product","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=62)"},{"llr":60.287,"date":"","count":13,"signal":"Accidental exposure to product by child","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=60)"},{"llr":48.53,"date":"","count":7,"signal":"Ergot poisoning","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=49)"},{"llr":44.393,"date":"","count":12,"signal":"Arteriospasm coronary","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=44)"},{"llr":42.982,"date":"","count":29,"signal":"Exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=43)"},{"llr":42.498,"date":"","count":9,"signal":"Postpartum haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=42)"}],"drugInteractions":[{"url":"/drug/amprenavir","drug":"amprenavir","action":"Avoid combination","effect":"May interact with Amprenavir, Methylergonovine","source":"DrugCentral","drugSlug":"amprenavir"},{"url":"/drug/conivaptan","drug":"conivaptan","action":"Avoid combination","effect":"May interact with Conivaptan, Methylergonovine","source":"DrugCentral","drugSlug":"conivaptan"},{"url":"/drug/mibefradil","drug":"mibefradil","action":"Avoid combination","effect":"May interact with Methylergonovine, Mibefradil Dihydrochloride","source":"DrugCentral","drugSlug":"mibefradil"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Methylergonovine, Nefazodone","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Avoid combination","effect":"May interact with Methylergonovine, Nelfinavir Mesylate","source":"DrugCentral","drugSlug":"nelfinavir"}],"commonSideEffects":[{"effect":"Hypertension","drugRate":"≥ several cases","severity":"serious"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"occasionally","severity":"unknown"},{"effect":"Vomiting","drugRate":"occasionally","severity":"unknown"},{"effect":"Acute myocardial infarction","drugRate":"reported","severity":"unknown"},{"effect":"Transient chest pains","drugRate":"reported","severity":"unknown"},{"effect":"Arterial spasm (coronary and peripheral)","drugRate":"reported","severity":"unknown"},{"effect":"Bradycardia","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Hematuria","drugRate":"reported","severity":"unknown"},{"effect":"Thrombophlebitis","drugRate":"reported","severity":"unknown"},{"effect":"Water intoxication","drugRate":"reported","severity":"unknown"},{"effect":"Hallucinations","drugRate":"reported","severity":"unknown"},{"effect":"Leg cramps","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Tinnitus","drugRate":"reported","severity":"unknown"},{"effect":"Nasal congestion","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Diaphoresis","drugRate":"reported","severity":"unknown"},{"effect":"Palpitation","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Foul taste","drugRate":"reported","severity":"unknown"},{"effect":"Seizure","drugRate":"≥ several cases","severity":"serious"},{"effect":"Headache","drugRate":"≥ several cases","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"reported","severity":"unknown"}],"contraindications":["Arteriosclerosis obliterans","Cerebrovascular accident","Disease of liver","Hypertensive disorder","Kidney disease","Pregnancy, function","Pregnancy-induced hypertension","Seizure disorder","Sepsis syndrome"],"specialPopulations":{"Pregnancy":"Use of methylergonovine maleate is contraindicated during pregnancy because of its uterotonic effects.","Geriatric use":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Hepatic impairment":"decreased hepatic"}},"trials":[],"aliases":[],"company":"Edison Theraps Llc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=methylergometrine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:04:59.613285+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:05:19.049534+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:05:06.126236+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=methylergometrine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:05:06.846153+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:04:58.480093+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:04:58.480121+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201356/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:05:07.545397+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA091577","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:04:58.480126+00:00"}},"allNames":"methergine","offLabel":[],"synonyms":["methylergometrine maleate","methylergonovine","methergine","methergen","methylergobasin","methylergobasine","methylergobrevin","partergin","methylergonovine maleate","methylergometrine","methylergometrin"],"timeline":[{"date":"1946-11-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Edison Theraps Llc)"}],"aiSummary":"Methylergometrine (Methergine), marketed by Edison Theraps LLC, is a postabortal hemorrhage treatment that activates the 5-hydroxytryptamine receptor 2A to induce vasoconstriction. Its key strength lies in its well-established mechanism of action and a strong patent protection until 2028. The primary risk is the presence of multiple off-patent competitors with similar mechanisms of action, such as amitriptyline and amoxapine, which may limit market share and pricing power.","approvals":[{"date":"1946-11-19","orphan":false,"company":"EDISON THERAPS LLC","regulator":"FDA"}],"brandName":"Methergine","ecosystem":[{"indication":"Postabortal Hemorrhage","otherDrugs":[],"globalPrevalence":null},{"indication":"Postpartum hemorrhage","otherDrugs":[{"name":"carboprost","slug":"carboprost","company":"Pharmacia And Upjohn"},{"name":"misoprostol","slug":"misoprostol","company":"Gd Searle Llc"},{"name":"oxytocin","slug":"oxytocin","company":"Novartis"}],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","novelty":"First-in-class","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR1F","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1F","protein":"5-hydroxytryptamine receptor 1F"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HTR1E","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1E","protein":"5-hydroxytryptamine receptor 1E"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"}],"modality":"Small Molecule","drugClass":"Ergot Derivative","explanation":"","oneSentence":"","technicalDetail":"Methergine exerts its effects by selectively activating the 5-HT2A receptor, a subtype of serotonin receptor, resulting in vasoconstriction and subsequent reduction in uterine blood flow."},"commercial":{"launchDate":"1946","_launchSource":"DrugCentral (FDA 1946-11-19, EDISON THERAPS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1764","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=methylergometrine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=methylergometrine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:39:40.663940","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:05:19.049806+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"brexpiprazole","drugSlug":"brexpiprazole","fdaApproval":"2015-07-10","patentExpiry":"Oct 12, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bromocriptine","drugSlug":"bromocriptine","fdaApproval":"1978-06-28","patentExpiry":"Jun 7, 2030","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"methylergometrine","indications":{"approved":[{"name":"Postabortal Hemorrhage","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Postpartum hemorrhage","source":"DrugCentral","snomedId":47821001,"regulator":"FDA","eligibility":{"Second stage of labor":"Under full obstetric supervision"}}],"offLabel":[{"name":"Incomplete miscarriage","source":"DrugCentral","drugName":"methylergometrine","evidenceCount":1,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"brexpiprazole","brandName":"brexpiprazole","genericName":"brexpiprazole","approvalYear":"2015","relationship":"same-target"},{"drugId":"bromocriptine","brandName":"bromocriptine","genericName":"bromocriptine","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07390864","phase":"NA","title":"Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy","status":"RECRUITING","sponsor":"Cairo University","startDate":"2026-01-18","conditions":["Myoma;Uterus"],"enrollment":40,"completionDate":"2026-08-30"},{"nctId":"NCT02910115","phase":"NA","title":"Cooling the Uterus in C-section After Dysfunctional Labor","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2015-05-14","conditions":["Blood Loss","Dysfunctional Labor","Uterine Atony"],"enrollment":8,"completionDate":"2018-11-10"},{"nctId":"NCT07318467","phase":"NA","title":"Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-01-01","conditions":["Post Partum Hemorrhage"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT03584854","phase":"PHASE4","title":"Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-03-01","conditions":["Postpartum Hemorrhage","Uterine Atony"],"enrollment":100,"completionDate":"2022-06-15"},{"nctId":"NCT05772156","phase":"PHASE4","title":"Prophylactic Methylergonovine for Twin Cesarean","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-03-07","conditions":["Twin; Complicating Pregnancy","Postpartum Hemorrhage"],"enrollment":66,"completionDate":"2024-03-11"},{"nctId":"NCT05236985","phase":"PHASE4","title":"Oxytocin Bolus Versus Infusion in Elective Cesarean Section\"","status":"RECRUITING","sponsor":"Stony Brook University","startDate":"2022-03-15","conditions":["Elective Cesarean Section"],"enrollment":120,"completionDate":"2024-12-15"},{"nctId":"NCT03390010","phase":"PHASE1","title":"Misoprostol Versus Active Management of Labour in CS","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2017-12-28","conditions":["Cesarean Section"],"enrollment":300,"completionDate":"2018-03-06"},{"nctId":"NCT03904446","phase":"PHASE4","title":"Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients","status":"COMPLETED","sponsor":"Cynthia Wong","startDate":"2019-06-08","conditions":["Uterine Atony With Hemorrhage"],"enrollment":160,"completionDate":"2021-02-15"},{"nctId":"NCT02044549","phase":"PHASE4","title":"Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-06","conditions":["Postpartum Hemorrhage","Blood Loss"],"enrollment":300,"completionDate":"2015-12"},{"nctId":"NCT03303235","phase":"EARLY_PHASE1","title":"Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2020-07","conditions":["Uterine Atony","Uterine Tone Disorders","Postpartum Hemorrhage"],"enrollment":0,"completionDate":"2020-12"},{"nctId":"NCT02408965","phase":"PHASE4","title":"Uterotonic Prophylaxis Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-03","conditions":["Hemorrhage"],"enrollment":284,"completionDate":"2017-03"},{"nctId":"NCT03939806","phase":"","title":"Effects of Oxytocin and Carbetocin on Renal System in Cesarean Sections","status":"UNKNOWN","sponsor":"Ufuk University","startDate":"2019-05","conditions":["Postpartum Hemorrhage"],"enrollment":100,"completionDate":"2019-06"},{"nctId":"NCT01549223","phase":"PHASE4","title":"Oxytocin And Uterotonic Agent Use For Cesarean Delivery","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-04","conditions":["Uterine Atony","Hypotension"],"enrollment":60,"completionDate":"2012-01"},{"nctId":"NCT02101567","phase":"PHASE4","title":"Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Haemorrhage Following Caesarean Section","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2014-05","conditions":["Bleeding","Anemia"],"enrollment":200,"completionDate":"2015-04"},{"nctId":"NCT00858832","phase":"NA","title":"Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2008-12","conditions":["Endometritis"],"enrollment":44,"completionDate":"2011-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"METHYLERGONOVINE MALEATE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Methylergonovine Maleate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Methylergonovine Maleate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"METHYLERGONOVINE MALEATE"},{"form":"TABLET","route":"ORAL","productName":"Methergine"},{"form":"TABLET","route":"ORAL","productName":"Methylergonovine Maleate"},{"form":"TABLET","route":"ORAL","productName":"methylergonovine maleate"},{"form":"TABLET, COATED","route":"ORAL","productName":"METHERGINE"},{"form":"TABLET, COATED","route":"ORAL","productName":"Methergine"}]},"crossReferences":{"NUI":"N0000179466","MMSL":"160889","NDDF":"001306","UNII":"W53L6FE61V","VUID":"4018757","CHEBI":"CHEBI:6874","VANDF":"4018757","INN_ID":"2900","RXNORM":"227555","UMLSCUI":"C0025760","chemblId":"CHEMBL1201356","ChEMBL_ID":"CHEMBL1201356","KEGG_DRUG":"D00680","DRUGBANK_ID":"DB00353","PDB_CHEM_ID":" H8D","PUBCHEM_CID":"8226","SNOMEDCT_US":"126074008","IUPHAR_LIGAND_ID":"150","SECONDARY_CAS_RN":"57432-61-8","MESH_DESCRIPTOR_UI":"D008755"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1946-","companyName":"Edison Theraps Llc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.85 hours","clearance":"7.18 mL/min/kg","bioavailability":"60%","volumeOfDistribution":"0.96 L/kg"},"publicationCount":232,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"G02AB01","allCodes":["G02AB01","G02AC01"]},"biosimilarFilings":[],"originalDeveloper":"Edison Theraps Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Edison Theraps Llc","companyId":"edison-theraps-llc","modality":"Small Molecule","firstApprovalDate":"1946","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1946-11-19T00:00:00.000Z","mah":"EDISON THERAPS LLC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1946-11-19T00:00:00.000Z","mah":"EDISON THERAPS LLC","brand_name_local":"METHERGINE","application_number":"NDA006035"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:05:19.049806+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}